Korean J Urol.  2012 Feb;53(2):78-81.

The Direct Anti-Cancer Effect of a Single Instillation of Epirubicin after Transurethral Resection of Bladder Tumor for Non-Muscle-Invasive Bladder Cancer

• Shin YS
• Kim JY
• Ko OS
• Doo AR
• Kim MK
• Jeong YB
• Kim HJ

Abstract

PURPOSE
To evaluate the direct anti-cancer effect of a single instillation of epirubicin (SIE) after transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC) by analysis of immediate urine cytology (IUC).
MATERIALS AND METHODS
We reviewed the records of 158 patients who had IUC after TURBT for NMIBC. Fifty-six patients were treated with SIE after TURBT and 102 patients were not treated with SIE. The direct anti-cancer effect of SIE was compared in the two groups according to the result of IUC. The relationship between SIE and IUC in NMIBC was analyzed by use of multivariate Cox proportional hazards regression models.
RESULTS
The IUC-positive rate was 33.9% in the SIE group and 42.1% in the non-SIE group (p=0.005). The IUC-positive rate was lower in the SIE group than in the non-SIE group for each factor, including tumor stage, tumor grade, tumor size, tumor multiplicity, and preoperative urine cytology. Multivariate Cox proportional hazards regression analysis revealed that SIE was significantly associated with a negative IUC result in patients with NMIBC (HR, 0.163) (p<0.001).
CONCLUSIONS
These results indicate the direct anti-cancer effect of SIE in patients who undergo TURBT for NMIBC.

Keyword

Epirubicin; Neoplasms; Urinary bladder

MeSH Terms

Epirubicin
Humans
Urinary Bladder
Urinary Bladder Neoplasms
Epirubicin

Reference

1. Seo HS, Lee NK, Jee SH. The effect of cigarette smoaking on bladder cancer in Korean: a prospective cohort study. Korean J Urol. 2005. 46:234–240.

2. Kim WJ, Chung JI, Hong JH, Kim CS, Jung SI, Yoon DK. Epidemiological study for urologic cancer in Korea (1998-2002). Korean J Urol. 2004. 45:1081–1088.

3. Yang SJ, Song PH, Kim HT. Comparison of deep biopsy tissue damage from transurethral resection of bladder tumors between bipolar and monopolar devices. Korean J Urol. 2011. 52:379–383.

4. Jone JS, Campbell SC. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). Campbell-Walsh urology. 2007. 9th ed. Philadelphia: Saunders;2447–2467.

5. Popert RJ, Goodall J, Coptcoat MJ, Thompson PM, Parmar MK, Masters JR. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Br J Urol. 1994. 74:195–199.

6. Abrams PH, Choa RG, Gaches CG, Ashken MH, Green NA. A controlled trial of single dose intravesical Adriamycin in superficial bladder tumours. Br J Urol. 1981. 53:585–587.

7. Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol. 1983. 129:505–509.

8. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993. 149:749–752.

9. Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986. 4:425–439.

10. Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol. 1997. 79:731–735.

11. Melekos MD, Dauaher H, Fokaefs E, Barbalias G. Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. J Urol. 1992. 147:371–375.

12. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E. Finnbladder Group. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study? FinnBladder III long-term results. J Urol. 2002. 168:981–985.

13. Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmäng S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol. 2008. 179:101–105.

14. Okamura K, Kinukawa T, Tsumura Y, Otani T, Itoh H, Kobayashi H, et al. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol. 1998. 33:285–288.

15. Nomata K, Noguchi M, Kanetake H, Tsuda N, Hayashi M, Yamashita S, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer Chemother Pharmacol. 2002. 50:266–270.

16. Akaza H. New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence. Gan To Kagaku Ryoho. 1997. 24:Suppl 1. 253–256.

17. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol. 2001. 165:1067–1077.

18. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2008. 2:212–221.

19. Shin YS, Kim SD, Cha JS, Kim MK, Jeong YB, Kim HJ. Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer. Int J Urol. 2011. 18:439–443.

20. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol. 1993. 150:60–64.